Halo Healthcare Inc.
Early detection of breast cancer
This article was originally published in Start Up
A women’s health care company in turnaround – one well recognized for assessing a woman’s risk of developing breast cancer through the HALO breast test – is developing a breast cancer diagnostic based on the presence of three protein biomarkers found in breast nipple aspirate fluid. The HALO Pivot diagnostic kit from Halo Healthcare Inc. is an in-office, noninvasive test for diagnosing cancer or a recurrence at a very early stage.
You may also be interested in...
SK Bioscience has received the world’s first approval of its in-house developed recombinant protein COVID-19 vaccine SKYCovione (GBP510), in its home market of South Korea, two years after it began development. Strong support from the domestic government and international cooperation helped pave the way.
Can-Fite’s A3AR agonist was inferior to Amgen’s Otezla by most efficacy measures, while Bristol Myers Squibb’s competing deucravacitinib is closer to approval and did beat Otezla.
The company’s lipid nanoparticle technology can deliver mRNA, gene editing and other cargoes to multiple cell and organ types. ReCode aims to expand its pipeline beyond lung diseases.